SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Satchel Paige — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientSatchel Paige
Date of birth1906-07-07
IdentifiersMRN HR-ML047-SYN-TD; SSN (made up) 000-47-3381
Document date1979-09-08
AuthorDelphine Whitaker-Osei, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Eight-week review: the new inhaler, rehabilitation, the screening CT and lipids. [S]

History of Present Illness

Mr. Paige returns six weeks after starting umeclidinium-vilanterol and eight weeks after starting atorvastatin. He takes the inhaler every morning and has not missed a dose; he has no dry mouth or trouble passing urine. He can now walk to the store without stopping, and uses albuterol two or three times a week. He has been to eight rehabilitation sessions and walks on the days between. He has had no flare-up. His low-dose CT five weeks ago showed emphysema in the upper lobes, a 4 mm nodule with a benign appearance, and calcium in the coronary arteries; he has no chest pain on exertion. He has had no muscle aches on atorvastatin. [S]

ElementDetail
SymptomsCAT 14, from 18; mMRC 1
Reliever useTwo or three times a week
Low-dose CTCentrilobular emphysema; 4 mm nodule, Lung-RADS 2; moderate coronary calcification
LipidsLDL 86 mg/dL, from 148

Review of Systems

SystemResultFinding
RespiratoryPositiveLess breathless; little morning sputum; no wheeze
CardiovascularNegativeNo chest pain, pressure or palpitations on exertion; no ankle swelling
GenitourinaryNegativeNo hesitancy or poor stream
MusculoskeletalNegativeNo muscle aches

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Albuterol 90 micrograms per inhalation metered-dose inhaler with a spacer, two inhalations every four hours as needed for breathlessnessTwo inhalations with a spacer every 4 hours as neededRespiratory tract route1979-07-14activeS
Umeclidinium 62.5 micrograms with vilanterol 25 micrograms dry powder inhaler (a LAMA with a LABA), one inhalation once a dayOne inhalation each morning; a strong, deep breath inRespiratory tract route1979-07-28activeS
Atorvastatin 20 mg tablet once a dayOne tablet each eveningOral route1979-07-14activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1979-09-08Body height191cmS
1979-09-08Body weight82.8kgS
1979-09-08Body mass index (BMI) [Ratio]22.7kg/m2S
1979-09-08Systolic blood pressure130mm[Hg]S
1979-09-08Diastolic blood pressure78mm[Hg]S
1979-09-08Heart rate78/minS
1979-09-08Respiratory rate16/minS
1979-09-08Body temperature36.6CelS
1979-09-08Oxygen saturation in Arterial blood by Pulse oximetry95%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1979-09-08Cholesterol [Mass/volume] in Serum or Plasma158mg/dL<=199 mg/dLNormalS
1979-09-08Cholesterol in HDL [Mass/volume] in Serum or Plasma46mg/dL>=40 mg/dLNormalS
1979-09-08Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation86mg/dL<=99 mg/dLNormalS
1979-09-08Triglyceride [Mass/volume] in Serum or Plasma130mg/dL<=149 mg/dLNormalS

Physical Exam

Vital signs recorded on 1979-09-08; see the Vital Signs section. [S]

SystemFinding
GeneralComfortable; blood pressure 130/78, pulse 78, oxygen saturation 95 percent on room air
RespiratoryReduced breath sounds; no wheeze or crackles
CardiovascularRegular rhythm; no edema
Inhaler techniqueDry powder inhaler used correctly with a strong, deep breath in and a breath-hold

Problems

ProblemClinical statusVerificationCodeProvenance
Breathlessness on exertion for about two years, now after one flight of stairs or a block on the level (mMRC 2), with a morning cough and a little clear sputum most days; no chest pain, ankle swelling, orthopnea, wheeze at rest or weight loss; a former smoker of about 30 pack-years; cause under evaluation with spirometry and a pulmonology consultationresolvedconfirmed R06.09S — Synthetic presenting problem anchored to his documented emphysema; superseded when spirometry at the consultation confirmed COPD.
Chronic obstructive pulmonary disease, GOLD grade 2 (post-bronchodilator FEV1/FVC 0.58, FEV1 61% predicted by the race-neutral GLI Global equations), GOLD group B (CAT 18, mMRC 2, no exacerbation in the past year); alpha-1 antitrypsin normal; blood eosinophils 0.08 x 10^3/uL; synthetic modern diagnosis linked to his documented emphysemaactiveconfirmed J44.9S — Synthetic modern diagnosis made at the consultation, anchored to his documented emphysema; its onset and course in the modern episode are synthetic.
Former cigarette smoker, about 30 pack-years, stopped eleven years ago on his own; no use sinceactiveconfirmed Z87.891S — Synthetic smoking history: whether he smoked is not documented in the sources read, so the history is synthetic and labeled as such.
Hyperlipidemia: LDL 148 mg/dL, HDL 44 and triglycerides 160 at intake; estimated 10-year cardiovascular risk about 18 percent; atorvastatin started by shared decisionactiveconfirmed E78.5S — Synthetic cardiovascular risk factor anchored to his documented heart trouble; not a claim about his real lipids.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveySymptoms: CAT and mMRC dyspnea scaleEvery visitCompleted todayCAT 14; mMRC 1
SurveyExacerbations in the past 12 months (moderate and severe) and GOLD groupEvery visitCompleted todayNone; group B
ExaminationPulse oximetry at restEvery visitCompleted today95 percent on room air
LaboratorySpirometry: post-bronchodilator FEV1/FVC and FEV1 % predicted (race-neutral GLI Global)At diagnosis, then at least yearly or with a clear changeUp to dateDiagnostic spirometry six weeks ago; repeat in a year
Self-managementSmoking status and cessation supportEvery visitCompleted todaySmoke-free
ExaminationBMI and nutritionEvery visitCompleted todayBMI 22.7
Medication safetyInhaler technique, adherence and side effects (dry mouth, urinary retention)Every visitCompleted todayCorrect technique; no missed doses; no dry mouth or urinary symptoms
ImagingLow-dose CT lung cancer screeningYearly at 50 to 80 with 20 or more pack-years, while within fifteen years of quittingCompleted todayDone five weeks ago: Lung-RADS 2 (4 mm solid nodule); emphysema; coronary calcification; next in twelve months
ReferralPulmonary rehabilitationOffer when mMRC is 2 or more, or CAT 10 or more; within three weeks of a hospital discharge for an exacerbationCompleted todayEight of twenty sessions completed
LaboratoryLipid panel after starting a statinFour to twelve weeks after starting, then yearlyCompleted todayTotal cholesterol 158, HDL 46, LDL 86, triglycerides 130 mg/dL
Medication safetyStatin safety: muscle symptomsEvery visitCompleted todayNo muscle aches
ExaminationECG and cardiovascular riskAt baseline; reassess after exacerbationsUp to dateNormal ECG at intake; coronary calcification noted on CT; no angina
Self-managementVaccines: influenza, pneumococcal, RSV, COVID-19, Tdap, zosterYearly reviewDueInfluenza, RSV, COVID-19 and zoster at the wellness visit in four weeks
ExaminationLong-term oxygen assessmentWhen resting PaO2 is 55 mm Hg or less (60 with cor pulmonale or polycythemia) or saturation 88 percent or less, confirmed twiceNot indicatedSaturation 95 percent; no change since the blood gas

Goal progress:

Guideline basis: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement (2023); CMID: Clinical Monitoring Intelligence Database, COPD and hyperlipidemia monographs (2026); Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023); Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020); A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation (LOTT) (2016); Racial Bias in Pulse Oximetry Measurement (2020); Lung Cancer: Screening (2021); Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022); Adult Immunization Schedule by Age (2026)

Follow-up: Wellness visit with vaccines in four weeks. Fifteen-week review in seven weeks. Next scheduled visit 1979-10-06: subsequent annual wellness visit. [S]